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in T Cells and Upregulates CTLA-4: Relevance for
Se´zary Syndrome
Heather M. Gibson1,2, Anjali Mishra2, Derek V. Chan1,2,3, Timothy S. Hake2, Pierluigi Porcu2,3,4 and
Henry K. Wong1,2,3
Highly regulated expression of the negative costimulatory molecule cytotoxic T-lymphocyte antigen-4 (CTLA-4) on
T cells modulates T-cell activation and proliferation. CTLA-4 is preferentially expressed in Th2 T cells, whose
differentiation depends on the transcriptional regulator GATA3. Se´zary syndrome (SS) is a T-cell malignancy
characterized by Th2 cytokine skewing, impaired T-cell responses, and overexpression of GATA3 and CTLA-4.
GATA3 is regulated by phosphorylation and ubiquitination. In SS cells, we detected increased polyubiquitinated
proteins and activated GATA3. We hypothesized that proteasome dysfunction in SS T cells may lead to GATA3 and
CTLA-4 overexpression. To test this hypothesis, we blocked proteasome function with bortezomib in normal T
cells, and observed sustained GATA3 and CTLA-4 upregulation. The increased CTLA-4 was functionally inhibitory in
a mixed lymphocyte reaction (MLR). GATA3 directly transactivated the CTLA-4 promoter, and knockdown of GATA3
messenger RNA and protein inhibited CTLA-4 induction mediated by bortezomib. Finally, knockdown of GATA3 in
patient’s malignant T cells suppressed CTLA-4 expression. Here we demonstrate a new T-cell regulatory pathway
that directly links decreased proteasome degradation of GATA3, CTLA-4 upregulation, and inhibition of T-cell
responses. We also demonstrate the requirement of the GATA3/CTLA-4 regulatory pathway in fresh neoplastic
CD4þ Tcells. Targeting of this pathway may be beneficial in SS and other CTLA-4-overexpressing T-cell neoplasms.
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INTRODUCTION
Cytotoxic T-lymphocyte antigen-4 (CTLA-4, CD152) is a T-
cell surface protein with homology to CD28 and binds with
high affinity to the B7 family of costimulatory ligands (Brunet
et al., 1987; Linsley et al., 1991, 1992a, b; Waterhouse et al.,
1995, 1996; Boulougouris et al., 1998; Carreno et al., 2000;
Teft et al., 2006; Keilholz, 2008). CTLA-4 functions by
transmitting inhibitory signals to the nucleus and sequestering
B7 molecules to control the proliferation of surrounding cells
(Oosterwegel et al., 1999; Carreno et al., 2000). In addition,
CTLA-4 has a critical role in the regulation of T-cell responses
via its expression on regulatory T cells (Takahashi et al.,
2000; Jonuleit et al., 2001). CTLA-4 knockout mice develop
a severe lymphoproliferative disorder and exhibit immune
hyperactivation (Tivol et al., 1995; Waterhouse et al., 1995).
Polymorphisms within the noncoding regions of the CTLA-4
gene leading to reduced messenger RNA (mRNA) levels have
been linked to autoimmune diseases (Lee et al., 2005;
Kavvoura et al., 2007; Balic et al., 2009).
Recent studies have shown that GATA3, a T-cell
transcription factor, regulates Th2 T-cell differentiation (Cook
and Miller, 2010; Hwang et al., 2010; Nakata et al., 2010;
Zhu, 2010; Yagi et al., 2011), but its relationship with CTLA-4
is unclear. CTLA-4 has been shown to be increased in normal
Th2 T cells and in malignant T cells from Se´zary syndrome
(SS), a type of cutaneous T-cell lymphoma with a Th2 bias
(Hahtola et al., 2006; Nebozhyn et al., 2006; Wong et al.,
2006; Chong et al., 2008). This raises the hypothesis that in
SS and other mature CD4þ T-cell malignancies increased
expression of CTLA-4 and Th2 cytokine skewing may be due
to aberrant or dysregulated expression of GATA3. GATA3
is highly regulated by posttranslational mechanisms and
has been shown to be modulated by the proteasome
pathway and by phosphorylation (Yamashita et al., 2005).
We have previously shown an important role of the NFAT1
transcription factor in the regulation of CTLA-4 expression
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in normal T cells (Gibson et al., 2007). However, we
hypothesize that additional transcription factors and regula-
tory pathways likely have a role in the induction and
expression of CTLA-4.
In this report, we present evidence showing that GATA3
regulates CTLA-4 expression and suggest that the proteasome
pathway has an important role in GATA3 regulation. We also
demonstrate that SS T cells have increased levels of poly-
ubiquinated proteins compared with normal T cells and higher
levels of GATA3, suggesting that abnormal proteasome
regulation of GATA3 may provide a mechanism for the
increased CTLA-4 expression in SS. To test this hypothesis,
we inhibited proteasome function in normal T cells with
bortezomib and observed sustained expression of CTLA-4 in
normal CD4þ T cells, mimicking the expression pattern
observed in SS. The increased CTLA-4 resulting from bortezo-
mib-mediated proteasome dysfunction is paralleled by in-
creased GATA3 expression. Furthermore, we demonstrate that
GATA3 can transactivate the CTLA-4 promoter and is directly
involved in the regulation of CTLA-4 transcription in normal
CD4þ T cells. Knockdown of GATA3 decreased bortezomib-
induced CTLA-4 expression. Taken together, this work intro-
duces a new mechanism for CTLA-4 regulation in SS T cells and
provides a potential mechanistic link between the abnormal
expression of GATA3 and increased CTLA-4 expression.
RESULTS
CTLA-4 and GATA3 expression is increased in SS T cells
To study the role of GATA3 in regulating CTLA-4 expression,
levels of GATA3 and CTLA-4 were measured in total RNA
isolated from peripheral blood mononuclear cells (PBMCs)
from patients with SS and controls (normal, healthy donors,
and psoriasis patients). CTLA-4 expression was stimulated
with phorbol 12-myristate 13-acetate (PMA)/A23187, direct
activators of cytoplasmic T-cell signaling pathways that
bypass defective surface signaling (Wong et al., 2006). From
quantitative real-time PCR (qRT-PCR) analysis, CTLA-4
transcription in SS samples was induced to a level that was
higher than normal PBMCs (Figure 1a). The expression of
CTLA-4 in PBMCs from psoriasis was similar to normal
controls, suggesting that increased CTLA-4 expression in
Se´zary cells was independent of chronic T-cell activation
secondary to inflammation.
Consistent with previous reports (Nebozhyn et al., 2006),
qRT-PCR showed that GATA3 transcript was increased
significantly in SS PBMCs, both at rest and following
stimulation (Po0.005, Figure 1b). Immunoblot analysis of
GATA3 protein levels in whole-cell extracts from unstimu-
lated PBMCs of SS patients (SS1–SS5) confirmed a correlation
between GATA3 protein levels and increased GATA3
transcription (Figure 1c, top panel). In addition, we also
measured the level of phospho-GATA3, the transcriptionally
active form, which has been suggested to have a role in
CTLA-4 expression in normal T cells (Yamashita et al., 2005).
We found that total protein extract from SS patients showed
an increase in the level of phospho-GATA3 compared with
normal T cells (Figure 1c).
CTLA-4 has also been shown to be regulated by NFAT1
and FoxP3 (Hori et al., 2003; Wu et al., 2006; Gibson et al.,
2007). However, analysis of NFAT1 and FoxP3 expression by
qRT-PCR and immunoblot analysis did not reveal significant
differences between SS and normal T cells (data not shown).
Although GATA3 has been shown to be regulated by the
ubiquitin–proteasome pathway (Yamashita et al., 2005),
proteasome function has not been evaluated in SS. When
total ubiquitin from whole-cell extracts was measured by
immunoblot analysis, a significant increase in poly-ubiqui-
nated proteins in SS cells compared with normal controls was
measured (Figure 1c).
Proteasome inhibitor induces CTLA-4 expression
Increased levels of poly-ubiquitinated proteins in SS T cells
suggested that altered proteasome function might have a role
in enhancing GATA3 and CTLA-4 expression. To determine
whether proteasome dysfunction alone is sufficient to alter
regulation of CTLA-4 in T cells, proteasome activity was
inhibited in normal CD4þ T cells using bortezomib, a
specific inhibitor of the 26S proteasome (Adams and
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Figure 1. Se´zary cells show dysregulation of cytotoxic T-lymphocyte antigen-4 (CTLA-4), GATA3, and proteasome activity relative to psoriasis and
normal controls. (a) CTLA-4 and (b) GATA3 messenger RNA levels are increased in peripheral blood mononuclear cells isolated from Se´zary patients
(triangles, n¼ 6) relative to psoriasis (squares, n¼ 6) and normal (diamonds, n¼ 6) controls that were stimulated with phorbol 12-myristate 13-acetate/A23187
for the indicated time points as measured by quantitative real-time PCR. Results are shown as the average fold increase over unstimulated normal cells±SEM
(*Po0.05). (c) Immunoblot analysis of purified CD4þ T-cell lysates from unstimulated normal donor (n¼ 2) CD4þ T cells and Se´zary (SS1–SS5) patients
using antibodies to probe for total GATA3, phospho-GATA3, total ubiquitin, and actin, as described in the Materials and Methods.
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Kauffman, 2004). Normal CD4þ T cells were stimulated
with PMA/A23187 in the presence of 10mM bortezomib,
and surface-bound CTLA-4 was assessed by flow cytometry
(Figure 2a). In bortezomib-treated CD4þ T cells, membrane-
bound CTLA-4 was higher than in untreated CD4þ T cells
(46.31% treated CD4þ vs. 13.32% untreated CD4þ ).
To study the kinetics of CTLA-4 expression following
PMA/A23187 stimulation and bortezomib treatment, a time-
course study was conducted (Figure 2b and c). Untreated
CD4þ T cells exhibited a peak in CTLA-4 expression
between 3 and 6 hours after stimulation, with a subsequent
rapid decline in CTLA-4. Incubation with bortezomib
led to a sustained higher level of CTLA-4 expression that
persisted beyond 12 hours after stimulation (Figure 2b and c).
Another proteasome inhibitor, ALLN, mediated an equivalent
increase in CTLA-4 expression (data not shown) and
demonstrated that the effect is not from the nonspecific
property of bortezomib but is from modulation of the
proteasome pathway.
Bortezomib-induced CTLA-4 expression suppresses T-cell
proliferation
To determine whether increased surface CTLA-4 in bortezo-
mib-treated cells could functionally suppress T-cell prolifera-
tion, a mixed lymphocyte reaction (MLR) was performed.
Purified CD4þ T cells were incubated for 9 hours with 0,
0.1, and 10mM of bortezomib and PMA/A23187 followed by
washing, which resulted in 9.1%, 15.9%, and 24.2% CTLA-4
expression, respectively. Although CTLA-4 expression dimin-
ished within 12 hours without bortezomib or PMA/A23187,
CTLA-4 expression remained elevated in 11.6% of cells at the
10 mM bortezomib-treated population after 24 hours (Figure
3a). In MLR assays, the bortezomib-treated cells suppressed
proliferation more effectively than untreated cells (Figure 3b).
Culturing with anti-CTLA-4 blocking antibody increased
proliferation in bortezomib-treated samples, whereas samples
without bortezomib were unaffected, confirming a CTLA-4-
specific, bortezomib-dependent mechanism.
Proteasome inhibition leads to increased CTLA-4 and GATA3
transcription
To study the effect of bortezomib-induced proteasome
dysfunction on CTLA-4 and GATA3 transcription, qRT-PCR
was performed to measure mRNA levels in stimulated cells
in the presence and absence of bortezomib (Figure 4a).
Although CTLA-4 expression peaked 3 hours after stimulation
in bortezomib-untreated CD4þ T cells, expression in
bortezomib pretreatment at various concentrations (0, 0.5,
1, 5, and 10 mM) led to CTLA-4 increase that peaked 12 hours
after simulation (Supplementary Figure S1 online). This
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Figure 2. Proteasome inhibition with bortezomib augments cytotoxic T-lymphocyte antigen-4 (CTLA-4) surface expression. (a) Bortezomib increases
CTLA-4 surface expression on normal primary CD4þ T cells after stimulation with 10mM bortezomib (right panel) compared with untreated cells (left panel).
Results are representative of at least six independent experiments. (b) CTLA-4 expression on phorbol 12-myristate 13-acetate/A23187-stimulated normal primary
T cells derived from a normal donor treated with 0 mM (red), 0.1 mM (green), and 10 mM (blue) of bortezomib over 3–12 hours as assessed by flow cytometry.
Results are representative of four independent experiments. (c) Summary of average CTLA-4 surface expression from the four individuals in b ±SEM in b
(**Po0.005).
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paralleled the GATA3 gene expression profile and was
consistent with a previous report (Yamashita et al., 2005).
When the mRNAs for other transcription factors reported to
participate in CTLA-4 expression were analyzed (Wu et al.,
2006; Gibson et al., 2007), neither NFAT1 nor FoxP3
expression differed in the presence of bortezomib (Supple-
mentary Figure S2a and b online).
T-cell transcription factors are differentially regulated by
proteasome inhibition
To investigate whether proteasome inhibition affected the
protein stability of NFAT1, FoxP3, or GATA3, whole-cell
lysates from normal CD4þ T cells were analyzed by
immunoblotting (Figure 4b). IkB served as a control to
monitor the efficiency of proteasome inhibition. Consistent
with flow cytometry analyses of surface-bound CTLA-4,
bortezomib induced a sustained increase in CTLA-4 protein
expression at each time point. NFAT1 protein was not
increased with bortezomib, but at high bortezomib concen-
trations a modest reduction was observed. Untreated samples
showed enhanced FoxP3 expression over the time course, but
expression was abrogated with bortezomib (Figure 4b).
After prolonged stimulation in the presence of bortezomib,
a higher-molecular-weight species of GATA3 appeared,
suggesting posttranslational modification (Figure 4b). GATA3
has been shown to be regulated by phosphorylation to form
the transcriptionally active protein (Maneechotesuwan et al.,
2007). To confirm the nature of the higher-molecular-weight
band, nuclear and cytosolic fractions were isolated from
T cells stimulated for 6 hours after treatment with bortezomib.
When analyzed for phospho(p)-S308 GATA3 by immuno-
blotting (Figure 4c), a significant band corresponding to p-
S308 GATA3 was detected after bortezomib treatment in the
nuclear fraction, which was greater than the corresponding
level in the cytosolic fractions. Total histone H3 immunoblot
served as a control to confirm the efficiency of isolating
nuclear and cytosolic fractions. Finally, intracellular flow
analysis of total GATA3 levels in stimulated cells after
bortezomib treatment confirmed that GATA3 remained
elevated 12 hours after bortezomib treatment and stimulation
(Figure 4d).
GATA3 enhances CTLA-4 expression through interaction with
the proximal promoter
To address whether GATA3 can directly affect CTLA-4
transcription, a CTLA-4 promoter reporter assay was per-
formed by cotransfecting a GATA3 expression vector with
luciferase reporter plasmids (pGL3) containing the proximal
CTLA-4 promoter into Jurkat T cells (Gibson et al., 2007).
Cotransfection of increasing amounts of GATA3 plasmid led
to a dose-dependent increase in CTLA-4 reporter gene
activity using a pGL3 construct with 380 bp of the proximal
CTLA-4 promoter (Po0.005, Figure 5a). Similar results were
obtained with a 1-kb CTLA-4 pGL3 promoter reporter
construct (data not shown). Cotransfection of GATA3 with
the SV40 pGL3 control vector or a promoterless vector did
not increase luciferase activity, demonstrating that the effect
is CTLA-4 specific (data not shown).
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Figure 3. Elevated cytotoxic T-lymphocyte antigen-4 (CTLA-4) with
bortezomib suppresses T-cell proliferation. (a) Primary CD4þ T cells were
isolated and treated with 0, 0.1, and 10 mM bortezomib concomitant with
phorbol 12-myristate 13-acetate (PMA)/A23187 stimulation over a 9-hour
incubation period. Cells were washed three times and returned to culture
media without bortezomib or PMA/A23187. CTLA-4 levels were measured at
the indicated time points. (b) Bortezomib-treated (0.1 mM and 10 mM) CD4þ
cells expressing higher levels of CTLA-4 better suppress proliferation
compared with untreated cells (0 mM) expressing lower levels of CTLA-4.
Washed cells were plated at a density of 5104 per well of a 96-well plate
and stimulated with an equal amount of mytomycin C–treated allogenic
peripheral blood mononuclear cells as detailed in the Materials and Methods.
Samples were supplemented with 0.5 mg IgG control (black bars) or CTLA-4
blocking antibody (white bars). After 7 days, proliferation was measured by
the MTS assay as described in Materials and Methods, and proliferation was
measured by absorbance at 570 nm. Results are presented as the averages of
quintuplicate samples ±SEM and are representative of three independent
experiments (**Po0.005). FSC, forward scatter. *Po0.05.
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To determine whether GATA3 interacts with the endo-
genous CTLA-4 promoter in primary T cells, we performed
chromatin immunoprecipitation (ChIP) assays. Using an
antibody to GATA3, we coimmunoprecipitated the CTLA-4
promoter in the presence of bortezomib (Figure 5b). This
suggests that GATA3 interacts with the CTLA-4 promoter
in vivo.
Targeting of GATA3 by small interfering RNA suppresses
CTLA-4 transcription
To verify the role of GATA3 in CTLA-4 expression in
bortezomib-treated CD4þ T cells, we targeted GATA3
expression with small interfering RNA (siRNA). Primary
CD4þ T cells were nucleoporated with GATA3-specific
or control scrambled siRNA, allowed to rest for 18 hours,
and then stimulated in the presence or absence of 10mM
bortezomib for 9 hours. GATA3 expression was reduced by
B50% with targeted siRNA at both the mRNA and protein
levels (Figure 6a and b). In these experiments, transcript
levels of CTLA-4 in bortezomib-treated cells were diminished
by 23.6% when GATA3 was depleted (Po0.05) but not
with stimulation alone (Figure 6c). IL-4, a GATA3-dependent
gene, served as control and was reduced consis-
tently (average of 40.9%, Po0.05) by mRNA qRT-PCR
(Supplementary Figure S3a online). Expression of the
internal control GAPDH was unaffected by GATA3-specific
siRNA in the same samples (Supplementary Figure S3b
online).
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We next determined the role of GATA3 in regulating the
CTLA-4 expression in fresh malignant T cells. In primary
CD4þCD45ROþCTLA4þ PBMCs from a patient with SS
(patient SS6) and a patient with another type of CTLA-4
overexpressing mature CD4þ peripheral T-cell leukemia,
nucleofection of siRNA against GATA3 suppressed CTLA-4
expression (Figure 6d and e). Nucleofection of scrambled
siRNA did not suppress CTLA-4 expression. These studies
support a role of GATA3 in CTLA-4 regulation in T-cell
malignancies.
DISCUSSION
SS is characterized by a defect of cellular immunity, low
production of IFN-g, IL-12, and other Th1 cytokines (Chong
et al., 2008). SS is associated with a Th2-skewed cytokine
profile with an increased expression of GATA3 and CTLA-4
(Nebozhyn et al., 2006; Wong et al., 2006; Kießling et al.,
2011). However, the mechanism leading to GATA3 and
CTLA-4 overexpression in SS has not been well character-
ized. In this study, we show that excessive polyubiquitination
of proteins can be detected in T cells from patients with SS,
and establish a mechanistic link between proteasome
dysfunction and overexpression of GATA3 and CTLA-4 in
fresh malignant T cells.
To better understand the interplay between the ubiqui-
tin–proteasome pathway and GATA3 and CTLA-4, we
inhibited proteasome function in normal T cells using
bortezomib. We have analyzed a number of cell lines, such
as Jurkat, Hut78, Hut 102, MyLa, and SeAx, and have not
found these cells to express CTLA-4; thus, primary cells were
chosen to study the role of GATA3 in CTLA-4 regulation
(Supplementary Figure S5 online). In CD4þ T cells, we
showed that surface-bound CTLA-4 expression increased
in the presence of bortezomib and that GATA3 regulates
CTLA-4 transcription. The increase was not due to bortezo-
mib-induced apoptosis in the time period necessary for
CTLA-4 induction (Supplementary Figure S4 online). In
addition, we showed that an increase in phosphorylation of
GATA3 at S308, the transcriptionally active form, accom-
panied this response in the presence of bortezomib. We
demonstrated via luciferase assays, ChIP analysis, and siRNA
knockdown experiments that GATA3 transactivated and
interacted with the CTLA-4 promoter. Moreover, in primary
malignant T cells that overexpressed CTLA-4, knockdown of
GATA3 could suppress CTLA-4 expression. Taken together,
these data delineate a new regulatory mechanism by which
proteasome inhibition increased CTLA-4 expression through
the stabilization and activation of GATA3. As CTLA-4 inhibits
T-cell proliferation, we then addressed whether the increased
surface-bound CTLA-4 in bortezomib-treated cells affected
T-cell proliferation. Bortezomib-treated cells showed sus-
tained surface expression of functionally active CTLA-4
over long intervals, and MLR assays showed increased
suppression by bortezomib-treated cells, thus supporting
the immunsuppression seen in T-cell malignancies that
overexpress CTLA-4.
We also identified a new mechanism for CTLA-4
transcriptional regulation: the interaction between GATA3
and the proximal promoter of the CTLA-4 gene. This mechan-
ism is supported indirectly by van Hamburg et al. (2009) with
studies of a GATA3-overexpressing mouse model in which
CTLA-4 expression was increased. However, we showed
directly in human T cells in transient promoter reporter assays
that transfection of GATA3 augmented luciferase activity with
380 bp of the CTLA-4 promoter, suggesting that GATA3 acted
at the proximal CTLA-4 promoter. ChIP assay results further
supported this mechanism. Sequence alignment identified
three potential GATA3-binding sites within the CTLA-4
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proximal promoter. However, DNA-binding assays did not
show GATA3 interacting with these sequences (data not
shown). Alternatively, GATA3 may not be in direct contact
with DNA. Previous studies have shown that GATA3 can act
cooperatively with NFAT1 to activate Th2 cytokines at NFAT
sites (Avni et al., 2002). There is evidence for direct
interaction between NFAT1 and GATA3 as demonstrated
by coimmunoprecipitation studies (Klein-Hessling et al.,
2008). These findings are consistent with the detection of
GATA3 by ChIP in a region in which we have previously
shown that NFAT1 has a role (Gibson et al., 2007).
The functional requirement for GATA3 was shown by
targeted inhibition of GATA3 by siRNA, which led to a
reduction in GATA3 mRNA and protein and reduced
expression of CTLA-4. This was a functionally significant
reduction, as confirmed by the measured effect on the
GATA3-dependent Th2 cytokine IL-4 in T cells. The
statistically significant reduction in CTLA-4 after GATA3
knockdown validates the importance of the role of GATA3 in
CTLA-4 activation in cells treated with bortezomib. Further-
more, inactivating GATA3 in primary neoplastic T cells can
reduce CTLA-4 expression and support the role of dysregu-
lated GATA3 in the increased CTLA-4 in T-cell malignancies.
An additional level of proteasome inhibition affecting
expression of GATA3 may be via the modulation of protein
kinases responsible for GATA3 activation, as phospho-
GATA3 increases in a dose-dependent manner with borte-
zomib. These data show that both stabilization of GATA3
protein and increased phosphorylation contribute to in-
creased CTLA-4 transcription.
In summary, we demonstrate that proteasome inhibition in
T cells leads to increased GATA3 expression, transcriptional
upregulation, and stabilization of surface-bound CTLA-4, and
suppression of normal T-cell growth in a MLR. This regulatory
pathway has significant relevance for T-cell malignancies that
overexpress CTLA-4, such as SS, which may be characterized
by accumulation of polyubiquitinated proteins, by increased
GATA3 and CTLA-4 expression and by defective T-cell
responses. In addition, although cutaneous T-cell lymphoma
has been shown to have abnormal expression of NF-kB, the
proteasome defect may lead to a compensatory increase in
I-kB, which would inhibit NF-kB function. This finding is
supported by the low expression of IL-2 in SS T cells, a gene
that is dependent on NF-kB (Chong et al., 2008). Thus, the
GATA3–CTLA-4 regulatory pathway described in this report
may serve as a therapeutic target for SS and other lymphoid
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Figure 6. GATA3 knockdown by small interfering RNA (siRNA) leads to decreased cytotoxic T-lymphocyte antigen-4 (CTLA-4) transcription. (a) siRNA
specific for GATA3 (siGATA3, dotted line) knocks down GATA3 expression compared with control siRNA (siCONTROL) induced in the presence of bortezomib.
Analysis of GATA3 protein was conducted by intracellular flow. Using the Amaxa system, 107 fresh CD4þ T cells were electroporated with 20 pmol control or
GATA3-targeted SMARTpool siRNA (Dharmacon) as described in Materials and Methods. Cells were allowed to rest for 18 hours, followed by stimulation for
9 hours with and without 10 mM bortezomib. Transcript levels of (b) GATA3 and (c) CTLA-4 under the conditions established in a were measured by quantitative
PCR for samples treated with siCONTROL (black bars) or siGATA3 (white bars) as previously described. Results are presented as averages of three independent
experiments ±SEM (*Po0.05). (d) CTLA-4-expressing Se´zary syndrome cells from patient SS6 show reduction of CTLA-4 when GATA3 is targeted by GATA-
specific siRNA as described in Materials and Methods. (e) CTLA-4-expressing peripheral T-cell leukemia cells show suppression of CTLA-4 when GATA3 is
knocked down with GATA-specific siRNA.
www.jidonline.org 255
HM Gibson et al.
Proteasome-Mediated GATA3 Upregulation of CTLA-4 in T Cells
malignancies characterized by CTLA-4-mediated immune
dysregulation.
MATERIALS AND METHODS
Isolation of primary CD4þ T cells and PBMCs
All patients gave written informed consent under an approved
research protocol in accordance with the Declaration of Helsinki
Principles and an approved institutional review board where
specimens were collected: the Henry Ford Hospital and Ohio State
University. All patient samples were obtained from patients with
established diagnosis of SS defined as erythroderma, lymphadeno-
pathy, and circulating Se´zary cells. The T-cell populations from SS
patients were analyzed previously by flow cytometry and showed
near homogeneity (Supplementary Table S1 online and Figure 6).
Normal CD4þ T cells were purified from leukopacks purchased
from the Red Cross using CD4þ T-cell Rosette Sep (15062, Stem
Cell Technologies, Vancouver, Canada) according to the manufac-
turer’s protocol. PBMCs from normal donors and Se´zary patients
were isolated using Ficoll as previously described (Wong et al.,
2006).
Cell culture
Cells were maintained in RPMI-1640 with 10% fetal fetal bovine
serum and 1% penicillin/streptomycin. All T-cell stimulations were
performed with 50 ng ml1 PMA and 1mg ml1 A23187. Bortezomib
(Millennium Pharmaceuticals, Cambridge, MA) was prepared at a
stock concentration of 2.5 mM.
RNA isolation, complementary DNA preparation, and qRT-PCR
Total RNA was isolated from PBMCs and used to generate
complementary DNA and perform qRT-PCR as previously described
(Wong et al., 2006). Expression levels were normalized relative to
B2-microglobulin for mRNA samples using the 2-ddCt method
(Livak and Schmittgen, 2001). Primers are shown in Supplementary
Table S2 online.
Protein lysates preparation and immunoblot analysis
Protein lysates were prepared, electrophoresed, probed, and
visualized as previously described (Wong et al., 2006). The
following primary antibodies were used for the immunoblots:
GATA3 (Abcam ab32858, Cambridge, MA), phospho-GATA3
(Abcam ab61052), Actin (Santa Cruz sc-1616, Santa Cruz, CA;
clone I-19), NFAT1 (Santa Cruz sc-7296, clone 4G6-G5), FoxP3
(Abcam ab20034, clone 236A/E7), polyubiquitin (Cell Signaling
3936, Danvers, MA; clone P4D1), phospho-I B-a (S32) (Cell
Signaling 2859, clone 14D4), CTLA-4 (Beckman Coulter IM2070,
Brea, CA; clone BNI3), or histone 3 (Cell Signaling 9717S, clone
3H1). Specific proteins were detected with an appropriate secondary
Ab (Santa Cruz sc-2354 and Pierce 32460 and 32430, Rockford, IL)
at 1:2,000 dilution in I-Block for 1.5 hours.
Flow cytometric analysis
Cells were stained for CD4þ (clone 13B8.2) and CTLA-4 (clone
BNI3) (obtained from Beckman Coulter IM2636U and BD 555853,
respectively) for 20 minutes, followed by washing with phosphate-
buffered saline and analysis on a FACS Calibur. Intracellular
expression was performed according to the manufacturer’s instruc-
tions (eBioscience, San Diego, CA) to detect FoxP3 and GATA3
(eBioscience 12-9966-42, clone TWAJ). Data were analyzed with the
FlowJo software (Ashland, OR).
Mixed lymphocyte reaction
Primary CD4þ T cells were PMA/A23187-stimulated with 0, 0.1,
and 10 mM bortezomib for 9 hours, and allogeneic PBMCs were
treated with 50mg ml1 mitomycin C for 30 minutes. Washed cells
were then plated in a 96-well flat-bottom plate at 5 105 PBMCs
mixed with 5 105 CD4þ cells per well in RPMI 1640 medium
with 10% fetal bovine serum. Samples were treated with 0.5 ı`g
CTLA-4 blocking antibody or mouse IgG2a control (Beckman
Coulter IM2070 and A55763, respectively). After 7 days, an MTS
assay (Promega G5421, Madison, WI) was performed, and
proliferation was measured via the A570.
Plasmids and reporter transcription analysis
CTLA-4 promoter constructs were cloned into the pGL3 luciferase
vector as previously described (Gibson et al., 2007). Promoterless
pGL3 basic and SV40-driven pGL3 control were used as controls.
The GATA3 expression vector was kindly received from Dr Gerd
Blobel. E1A 12S wild-type and mutant constructs were described
previously (Wong and Ziff, 1994). Jurkat cells were seeded in six-
well plates at 1.5 106 cells per sample in serum-free RPMI-1640.
One microgram CTLA-4 380-bp luciferase construct was transfected
into each sample with increasing concentrations (0, 0.5, 1, 2, and
3mg) of GATA3 expression vector or vector control plasmid in
triplicate using Lipofectin (Invitrogen, Grand Island, NY) according
to the manufacturer’s protocol. Cells were lysed in luciferase lysis
buffer (25 mM glycylglycine, 15 mM MgSO4, 4 mM EGTA, 1% Triton
X-100) with dithiothreitol added to 1 mM immediately before use,
and equal protein concentrations were subjected to luciferase
analysis. The luciferase level was determined using a Lumat LB
9501 luminometer (Berthod Technologies, Oak Ridge, TN) as
described previously (Ausubel et al., 2003).
ChIP assay
Cells were treated as indicated and fixed for 10 minutes in 1% forma-
ldehyde to cross-link protein and DNA complexes. The reaction was
quenched with the addition of 1.25 M glycine for 5 minutes. Cells
were pelleted and resuspended in radioimmunoprecipitation assay
buffer (50mM Tris, pH 7.4, 150mM NaCl, 1% NP-40, 1% SDS). Samples
were sonicated to shear DNA fragments to within 200–1,000 bp,
centrifuged to remove cellular debris, and diluted 10-fold with ChIP
dilution buffer to reduce SDS concentration. Immunoprecipitations
were performed using the ChIP Assay Kit (Millipore, Billerica, MA),
antibodies to GATA3 (Santa Cruz), and isotype control antibodies
(Millipore), as necessary. Immunoprecipitated DNA fragments were
purified with QiaQuick gDNA columns (Qiagen, Valencia, CA) and
evaluated by PCR or qRT-PCR with primers specific to the CTLA-4
promoter as indicated in Supplementary Table SI online.
Nucleic acid electroporation
Primary CD4þ T cells were electroporated with 107 cells using the
Amaxa system (Koeln, Germany) at a setting of U014 and the Amaxa
Human T Cell Kit for each sample. Expression plasmids for GATA3
or control vector were electroporated at 2 mg per sample. siRNA was
electroporated at 20 pmol per sample SmartPool siRNA directed at
GATA3 or off-target control (Dharmacon, Chicago, IL). After
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electroporation, cells were transferred to RPMI 1640 culture media
with 10% fetal bovine serum and allowed to rest for 18 hours.
Statistical analysis
A Student’s t-test (two-tailed, unequal variance) was used to analyze
the significance of differences between two experimental groups.
Data with a P-value of 0.05 or less were considered to be significant.
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